×
Home
Archive Submission Guidelines
News Contact
Review article
Crossmark

MicroRNA: Potential biomarkers in chronic kidney disease

By
Vladana Stojiljković ,
Vladana Stojiljković

University of Nis , Niš , Serbia

Nikola Stefanović Orcid logo ,
Nikola Stefanović

University of Nis , Niš , Serbia

Marija Vukelić-Nikolić Orcid logo ,
Marija Vukelić-Nikolić

University of Nis , Niš , Serbia

Branka Đorđević Orcid logo ,
Branka Đorđević

University of Nis , Niš , Serbia

Jelena Bašić Orcid logo ,
Jelena Bašić

University of Nis , Niš , Serbia

Gordana Kocić Orcid logo ,
Gordana Kocić

University of Nis , Niš , Serbia

Tatjana Cvetković Orcid logo
Tatjana Cvetković

University of Nis , Niš , Serbia

Abstract

Standard biomarkers for the diagnosis and follow-up of chronic kidney disease patients are appropriate neither in early diagnostics, adequate follow-up and progression assessment nor in complication development risk assessment. For that reason, a search for new, more suitable biomarkers continues. Various studies suggested microRNAs as a potential solution, as they are involved in the pathogenesis of diabetic nephropathy, kidney cancer and kidney function impairment in general. Internet search engines were used to find and select relevant literature data and electronic databases. Research published so far, in oncology especially, have reported various single microRNAs and panels of microRNAs as candidates for routine diagnostic implementation. Chronic kidney disease is, however, quite complex in terms of etiology of the disease occurrence, since there are many causes that can lead to kidney tissue damage and impairment of its function and finally full development of the chronic kidney disease. MicroRNAs are stable in bodily fluids, and hemodialysis procedure does not affect their levels. Also, high RNase activity in chronic kidney disease patients does not accelerate microRNA degradation in their samples. Literature data suggest that microRNAs are appropriate candidates for diagnostic use in chronic kidney disease. However, there are challenges that are yet to be overcome in order to use microRNAs routinely.

References

1.
Muendlein A, Geiger K, Leiherer A, Saely CH, Fraunberger P, Drexel H. Evaluation of the associations between circulating microRNAs and kidney function in coronary angiography patients. American Journal of Physiology-Renal Physiology. 2020;318(2):F315–21.
2.
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. The Lancet. 2013;382(9888):260–72.
3.
Jin J, Ku YH, Kim Y, Kim Y, Kim K, Lee JY, et al. Differential Proteome Profiling Using iTRAQ in Microalbuminuric and Normoalbuminuric Type 2 Diabetic Patients. Experimental Diabetes Research. 2012;2012:1–31.
4.
Sayilar EI. Biomarker Potential of Urine miR-451 at Different Stages of Diabetic Nephropathy. Journal of Diabetes & Metabolism. 07(02).
5.
Cui C, Cui Y, Fu Y, Ma S, Zhang S. Microarray analysis reveals gene and microRNA signatures in diabetic kidney disease. Molecular Medicine Reports.

Citation

Article metrics

Google scholar: See link

Citations

Crossref Logo

1

Crossref Logo

Nikola Stefanović, Katarina Danković, Radmila Veličković-Radovanović, Marija Vukelić-Nikolić, Maša Jović, Stevan Vujić, Vladana Stojiljković, Branka Mitić, Tatjana Cvetković

(2026)

Urinary MicroRNA Expression and Tacrolimus Pharmacokinetic Variability in Kidney Transplant Recipients: A Cross-sectional Study

Clinical Drug Investigation, ()

10.1007/s40261-026-01544-0

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.